Information:
Fel:
ID
14538
Beskrivning
Improving Memory in Patients With Multiple Sclerosis; ODM derived from: https://clinicaltrials.gov/show/NCT00062972
Länk
https://clinicaltrials.gov/show/NCT00062972
Nyckelord
Versioner (1)
- 2016-04-19 2016-04-19 -
Uppladdad den
19 april 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Multiple Sclerosis NCT00062972
Eligibility Multiple Sclerosis NCT00062972
- StudyEvent: Eligibility
Similar models
Eligibility Multiple Sclerosis NCT00062972
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Multiple sclerosis
Item
ms as defined by the poser criteria
boolean
C0026769 (UMLS CUI [1])
Edss
Item
expanded disability status scale (edss) score of 0 to 6.5
boolean
C0451246 (UMLS CUI [1])
Neurologic function
Item
stable neurologic function for at least 30 days prior to study entry
boolean
C0746866 (UMLS CUI [1])
Compliance
Item
agree to continue all current medications for study duration
boolean
C1321605 (UMLS CUI [1])
Rey auditory verbal learning test score
Item
rey auditory verbal learning test score in low normal range or below
boolean
C3640276 (UMLS CUI [1])
Mini-mental status
Item
mini-mental status exam score of 26 or higher
boolean
C2225229 (UMLS CUI [1])
Montgomery-asberg depression scale
Item
montgomery-asberg depression scale scaled score of 14 or lower
boolean
C2960593 (UMLS CUI [1])
Language
Item
fluent in english
boolean
C1145677 (UMLS CUI [1])
Anticholinergic or benzodiazepine medication
Item
use of anticholinergic or benzodiazepine medication
boolean
C0242896 (UMLS CUI [1])
C0005064 (UMLS CUI [2])
C0005064 (UMLS CUI [2])
Dosage change affecting cognitive function
Item
change in dosage of medications judged to have the potential to impact cognitive function (e.g., antispasticity medications) within 2 weeks of study entry
boolean
C2169453 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0392335 (UMLS CUI [1,3])
C0392760 (UMLS CUI [1,2])
C0392335 (UMLS CUI [1,3])
Substance use disorder
Item
current alcohol or substance abuse
boolean
C0038586 (UMLS CUI [1])
Comorbidity affecting cognitive functioning
Item
history of neurological or major medical problem that has a known effect on cognitive functioning
boolean
C0009488 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0392335 (UMLS CUI [1,3])
C0392760 (UMLS CUI [1,2])
C0392335 (UMLS CUI [1,3])
Compliance
Item
history of noncompliance
boolean
C1321605 (UMLS CUI [1])
Visual or upper extremity impairment
Item
visual or upper extremity impairment which precludes ability to participate in cognitive assessment
boolean
C3665347 (UMLS CUI [1])
C2051684 (UMLS CUI [2])
C2051692 (UMLS CUI [3])
C2051684 (UMLS CUI [2])
C2051692 (UMLS CUI [3])